Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, discusses how closed-loop artificial pancreas systems can help reduce the burden of type 1 diabetes (T1D) management during pregnancy.
Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, discusses the risks associated with hypoglycemia and hyperglycemia in pregnant patients with type 1 diabetes (T1D), as well as how a closed-loop insulin delivery system, or artificial pancreas, can help reduce the burden of T1D management during pregnancy.
Levister and colleagues at Mount Sinai have collaborated with other institutions to customize an artificial pancreas system for pregnant patients with T1D, who have tighter glucose targets compared with people with T1D who are not pregnant. Clinical trials were conducted by a consortium including Mount Sinai; Mayo Clinic in Rochester, Minnesota; and the Sansum Diabetes Research Institute in Santa Barbara, California.
Transcript
What are the risks associated with managing type 1 diabetes in pregnancy, and how are these addressed in a closed-loop system?
Because the glucose targets during pregnancy are tighter and on the lower side compared to those outside of pregnancy, there is a risk for hypoglycemia, or low blood sugar, when you have a system that's being more aggressive in terms of managing glucose and keeping it on the lower side as opposed to higher. One of the concerns that you have—not just with a closed-loop system, but when a woman is managing diabetes, either with injections or a insulin pump that is not part of a closed-loop system, or artificial pancreas system—is you have concern for severe low blood sugars that can lead to loss of consciousness or seizure. This was also a concern that we had for our participants in the study.
One of the things about a closed-loop system is that it can decrease, or stop, insulin delivery when the glucose was predicted to go below a certain level, and that will help with preventing hypoglycemia. This can still occur, but we did see a reduction in hypoglycemia in those that use the system compared to prior when they were not using the system.
A few of the concerns in regards to hyperglycemia during pregnancy are preeclampsia for the mother, medically indicated preterm delivery for the unborn child. You have risk for the child being born large for gestational age, which increases the need for cesarean section. And for those that are vaginally delivered, you have a higher risk for something called shoulder dystocia, where the shoulder can get caught in the birth canal during delivery and cause trauma to the child. You also have concerns for things like fetal death for placental malfunction and for delayed lung maturity. Those are all concerns that we have. That's one of the things that's driving us to help these patients to have an increased percent of time within target range to help prevent those complications from occurring.
And of course, the other thing that we want to do is, we want to help to relieve the patient's burden. You're always going to be thinking about glucoses and the safety of your baby during pregnancy with type 1 diabetes—I think that's something that we can't get rid of. But if a patient has the sense that they have a system that they're working with that can prevent them from having severe low blood sugars, potentially that can reduce their risk of having really high blood sugars, maybe it allows them to have a little less burden in regard to the both emotional impact and then just the day-to-day impact in regard to management. Maybe it allows them to partake in activities that they wouldn't usually partake in because they'd have concerns about it—and also just get a better night's sleep because they don't have as many concerns about running really high overnight or running really low overnight.
Reference
Levy CJ, Kudva YC, Ozaslan B, et al. At-home use of a pregnancy-specific zone-MPC closed-loop system for pregnancies complicated by type 1 diabetes: a single-arm, observational multicenter study. Diabetes Care. 2023;46(7):1425-1431. doi:10.2337/dc23-0173
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More